Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing
As genetic engineering and DNA manipulation tools like CRISPR continue to advance, the distinction between what science ‘could’ and ‘should’ do becomes murkier.